Skip to main content
Top
Published in: Breast Cancer Research 3/2010

01-10-2010 | Poster presentation

Promoting early symptomatic presentation in older women with breast cancer in the NHS breast screening programme

Authors: LJL Forbes, L Atkins, S Sellars, J Patnick, L Tucker, AJ Ramirez

Published in: Breast Cancer Research | Special Issue 3/2010

Login to get access

Excerpt

Women over 70 have poorer breast cancer survival than younger women, and this may be due to late stage at presentation [1]. Promoting early presentation with symptoms in older women attending for their final round of breast screening may reduce stage at diagnosis cost-effectively, and is unlikely to lead to overdiagnosis. We tested the efficacy of the 10-minute radiographer-delivered Promoting Early Presentation (PEP) Intervention to promote early presentation by increasing breast cancer awareness in the NHS Breast Screening Programme. …
Literature
1.
go back to reference Moller H, Sandin F, Bray F, Klint A, Linklater KM, Purushotham A, Robinson D, Holmberg L: Breast cancer survival in England, Norway and Sweden: a population-based comparison. Int J Cancer. 2010, 127: 2630-2638. 10.1002/ijc.25264.CrossRefPubMed Moller H, Sandin F, Bray F, Klint A, Linklater KM, Purushotham A, Robinson D, Holmberg L: Breast cancer survival in England, Norway and Sweden: a population-based comparison. Int J Cancer. 2010, 127: 2630-2638. 10.1002/ijc.25264.CrossRefPubMed
Metadata
Title
Promoting early symptomatic presentation in older women with breast cancer in the NHS breast screening programme
Authors
LJL Forbes
L Atkins
S Sellars
J Patnick
L Tucker
AJ Ramirez
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 3/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2660

Other articles of this Special Issue 3/2010

Breast Cancer Research 3/2010 Go to the issue

Poster presentation

Educational abstract

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine